JP2006521793A - Egfrインヒビター薬物に応答性の遺伝子発現マーカー - Google Patents

Egfrインヒビター薬物に応答性の遺伝子発現マーカー Download PDF

Info

Publication number
JP2006521793A
JP2006521793A JP2006503407A JP2006503407A JP2006521793A JP 2006521793 A JP2006521793 A JP 2006521793A JP 2006503407 A JP2006503407 A JP 2006503407A JP 2006503407 A JP2006503407 A JP 2006503407A JP 2006521793 A JP2006521793 A JP 2006521793A
Authority
JP
Japan
Prior art keywords
cancer
expression
gene
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006521793A5 (cg-RX-API-DMAC7.html
Inventor
デービッド アガス,
スティーブ シャク,
モウリーン ティー. クロニン,
ジョフレ ビー. ベイカー,
Original Assignee
ゲノミック ヘルス, インコーポレイテッド
セダーズ−シナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゲノミック ヘルス, インコーポレイテッド, セダーズ−シナイ メディカル センター filed Critical ゲノミック ヘルス, インコーポレイテッド
Publication of JP2006521793A publication Critical patent/JP2006521793A/ja
Publication of JP2006521793A5 publication Critical patent/JP2006521793A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2006503407A 2003-02-06 2004-02-05 Egfrインヒビター薬物に応答性の遺伝子発現マーカー Pending JP2006521793A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44596803P 2003-02-06 2003-02-06
PCT/US2004/003596 WO2004071572A2 (en) 2003-02-06 2004-02-05 Gene expression markers for response to egfr inhibitor drugs

Publications (2)

Publication Number Publication Date
JP2006521793A true JP2006521793A (ja) 2006-09-28
JP2006521793A5 JP2006521793A5 (cg-RX-API-DMAC7.html) 2007-03-22

Family

ID=32869443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503407A Pending JP2006521793A (ja) 2003-02-06 2004-02-05 Egfrインヒビター薬物に応答性の遺伝子発現マーカー

Country Status (6)

Country Link
US (2) US20040157255A1 (cg-RX-API-DMAC7.html)
EP (1) EP1590487A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006521793A (cg-RX-API-DMAC7.html)
AU (2) AU2004211955B2 (cg-RX-API-DMAC7.html)
CA (1) CA2515096A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004071572A2 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064702A1 (ja) * 2008-12-05 2010-06-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー
WO2010084998A1 (en) * 2009-01-26 2010-07-29 Kyushu University, National University Corporation A method of predicting the efficacy of a drug
JP2014526680A (ja) * 2011-09-12 2014-10-06 ユニヴェルシテイト ヘント 結腸直腸ガンのニューレグリン−1に基づく予後予測及び治療層別化
JP2017161531A (ja) * 2007-10-19 2017-09-14 セル・シグナリング・テクノロジー・インコーポレイテツド 癌の分類および使用法
KR20180010138A (ko) * 2016-07-20 2018-01-30 연세대학교 산학협력단 암 예후 예측을 위한 조성물 및 이를 포함하는 키트

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059012A1 (en) * 2002-07-31 2005-03-17 Daniel Afar Diagnosis of ZD1839 resistant tumors
US7505948B2 (en) * 2003-11-18 2009-03-17 Aureon Laboratories, Inc. Support vector regression for censored data
US7321881B2 (en) * 2004-02-27 2008-01-22 Aureon Laboratories, Inc. Methods and systems for predicting occurrence of an event
US7467119B2 (en) * 2003-07-21 2008-12-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
WO2005050563A2 (en) * 2003-11-17 2005-06-02 Aureon Biosciences Corporation Pathological tissue mapping
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
JP5422120B2 (ja) 2004-05-27 2014-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
WO2006020627A1 (en) * 2004-08-11 2006-02-23 Aureon Laboratories, Inc. Systems and methods for automated diagnosis and grading of tissue images
EP1812589A2 (en) * 2004-09-30 2007-08-01 Epigenomics AG Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders
WO2006045991A1 (en) * 2004-10-25 2006-05-04 Astrazeneca Ab Method to predict whether a tumor will react to a chemotherapeutic treatment
WO2006101925A2 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
US7449442B2 (en) * 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
JP2007252312A (ja) * 2006-03-24 2007-10-04 Japan Health Science Foundation 上皮成長因子受容体−チロシンキナーゼ阻害剤に対する肺ガンの感度測定方法および肺ガン治療剤のスクリーニング方法
DE102006048249A1 (de) * 2006-08-10 2008-02-14 Wolff Prof. Dr. Schmiegel Biomarker für Leberentzündung
US20080076134A1 (en) * 2006-09-21 2008-03-27 Nuclea Biomarkers, Llc Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
EP2157971B1 (en) * 2007-04-13 2012-01-11 Rikshospitalet- Radiumhospitalet HF Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer
US8377636B2 (en) 2007-04-13 2013-02-19 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to kinase inhibitors
NZ582618A (en) 2007-07-13 2012-07-27 Prometheus Lab Inc Drug selection for lung cancer therapy using antibody-based arrays
KR20100037637A (ko) * 2007-08-14 2010-04-09 에프. 호프만-라 로슈 아게 Egfr 억제제 치료에 대한 예측 마커
JP2010535516A (ja) * 2007-08-14 2010-11-25 エフ.ホフマン−ラ ロシュ アーゲー Egfr阻害剤治療のための予測マーカー
JP5421260B2 (ja) * 2007-08-14 2014-02-19 エフ.ホフマン−ラ ロシュ アーゲー Egfr阻害剤治療のための予測マーカー
AU2008286337B2 (en) * 2007-08-14 2011-10-27 F. Hoffmann-La Roche Ag Predictive marker for EGFR inhibitor treatment
AU2008307634A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
KR101620642B1 (ko) * 2007-11-07 2016-05-12 제넨테크, 인크. 항-cd40 항체를 사용한 치료에 대한 b-세포 림프종의 반응성 평가를 위한 방법 및 조성물
EP2065475A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
NZ589143A (en) * 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
WO2010015536A1 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
KR100996994B1 (ko) * 2008-08-18 2010-11-25 울산대학교 산학협력단 간세포암종 수술후 재발 또는 재발 발병 위험성의 진단방법
US20110171124A1 (en) * 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010121231A1 (en) 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
US10731221B2 (en) 2009-12-11 2020-08-04 Dignity Health Diagnosing IDH1 related subgroups and treatment of cancer
US20120252856A1 (en) * 2009-12-11 2012-10-04 Dignity Health Pi3k/akt pathway subgroups in cancer: methods of using biomarkers for diagnosis and therapy
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012097368A2 (en) * 2011-01-14 2012-07-19 Response Genetics, Inc. Her3 and her4 primers and probes for detecting her3 and her4 mrna expression
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ,エルエルシー 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
SG2014011316A (en) 2011-08-31 2014-06-27 Genentech Inc Diagnostic markers
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
JP2014531213A (ja) 2011-09-30 2014-11-27 ジェネンテック, インコーポレイテッド 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるegfrキナーゼ阻害薬に対する応答
CN104946597A (zh) * 2015-03-23 2015-09-30 大连医科大学附属第一医院 稳定表达GFP的shRNA靶向干扰YB-1基因人肺腺癌A549细胞株
CN106680515B (zh) * 2016-10-21 2018-06-12 杭州金式麦生物科技有限公司 用于肺癌诊断的多分子标志物组合

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
JP3944241B2 (ja) * 1995-12-18 2007-07-11 スージェン・インコーポレーテッド Aur―1および/またはaur―2関連疾患の診断および処置
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6203993B1 (en) * 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5861278A (en) * 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) * 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
EP1276901A2 (en) * 2000-01-13 2003-01-22 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US6618679B2 (en) * 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
US7157227B2 (en) * 2000-03-31 2007-01-02 University Of Louisville Research Foundation Microarrays to screen regulatory genes
AU2001280008A1 (en) * 2000-07-21 2002-02-05 Global Genomics Ab A method and an algorithm for mRNA expression analysis
WO2002024867A2 (en) * 2000-09-22 2002-03-28 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US20040076984A1 (en) * 2000-12-07 2004-04-22 Roland Eils Expert system for classification and prediction of generic diseases, and for association of molecular genetic parameters with clinical parameters
JP4368110B2 (ja) * 2001-01-12 2009-11-18 エール ユニヴァーシティ 癌患者の生物学的流体中のサバイビンの検出
US7776518B2 (en) * 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
KR20030094281A (ko) * 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
CN1612936A (zh) * 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6009045162, 日本癌学会総会記事,第61巻,第166頁,1057(2002年8月) *
JPN6009061797, European Journal of Cancer, 2002, Vol.38, p.S4 *
JPN6009061798, 第54回日本胸部外科学会総会, 2001, p.322 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017161531A (ja) * 2007-10-19 2017-09-14 セル・シグナリング・テクノロジー・インコーポレイテツド 癌の分類および使用法
WO2010064702A1 (ja) * 2008-12-05 2010-06-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー
WO2010084998A1 (en) * 2009-01-26 2010-07-29 Kyushu University, National University Corporation A method of predicting the efficacy of a drug
JP2014526680A (ja) * 2011-09-12 2014-10-06 ユニヴェルシテイト ヘント 結腸直腸ガンのニューレグリン−1に基づく予後予測及び治療層別化
KR20180010138A (ko) * 2016-07-20 2018-01-30 연세대학교 산학협력단 암 예후 예측을 위한 조성물 및 이를 포함하는 키트
KR101941054B1 (ko) 2016-07-20 2019-01-23 연세대학교 산학협력단 암 예후 예측을 위한 조성물 및 이를 포함하는 키트

Also Published As

Publication number Publication date
WO2004071572A3 (en) 2005-01-13
EP1590487A2 (en) 2005-11-02
AU2009208748A1 (en) 2009-09-10
US20080176229A1 (en) 2008-07-24
AU2004211955A1 (en) 2004-08-26
US20040157255A1 (en) 2004-08-12
CA2515096A1 (en) 2004-08-26
AU2004211955B2 (en) 2009-05-14
WO2004071572A2 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
JP4606879B2 (ja) Egfr陽性癌の遺伝子発現プロファイリング
AU2004211955B2 (en) Gene expression markers for response to EGFR inhibitor drugs
JP2006521793A5 (cg-RX-API-DMAC7.html)
US20080318230A1 (en) Gene expression markers for response to egfr inhibitor drugs
JP4723472B2 (ja) 乳癌予後診断のための遺伝子発現マーカー
JP5486719B2 (ja) 結腸直腸癌の予後のための遺伝子発現マーカー
JP4680898B2 (ja) 癌再発の可能性の予測
JP2006506093A5 (cg-RX-API-DMAC7.html)
US20070128636A1 (en) Predictors Of Patient Response To Treatment With EGFR Inhibitors
US20120004127A1 (en) Gene expression markers for colorectal cancer prognosis
HK1148320A (en) Gene expression markers for response to egfr inhibitor drugs

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090501

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100423